A functional polymorphism in UGT1A1 related to hyperbilirubinemia is associated with a decreased risk for Crohn's disease

Journal of Crohn's and Colitis

Volumn 6, Issue 5, 2012, Pages 597-602

  de Vries, Hilbert S ^a   te Morsche, Rene H M ^a   Jenniskens, Kevin ^a   Peters, Wilbert H M ^a   de Jong, Dirk J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Crohn's disease; Genetic polymorphism; Inflammatory bowel disease; UDP glucuronosyltransferase; Ulcerative colitis

Indexed keywords

ANTIOXIDANT; AZATHIOPRINE; BILIRUBIN; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A1; MERCAPTOPURINE; TIOGUANINE;

ABDOMINAL PAIN; ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DIZZINESS; ENZYME BLOOD LEVEL; FATIGUE; FEMALE; FEVER; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HERPES ZOSTER; HOMOZYGOSITY; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; PROMOTER REGION; PYREXIA IDIOPATHICA; RASH; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; ULCERATIVE COLITIS; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; BILIRUBIN; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; DNA; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HOMOZYGOTE; HUMANS; HYPERBILIRUBINEMIA; MALE; MIDDLE AGED; NETHERLANDS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PREVALENCE; PROMOTER REGIONS, GENETIC; RISK FACTORS; YOUNG ADULT;

EID: 84860842097     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.11.010     Document Type: Article

References (46)

1. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
2. Rezaie A., Parker R.D., Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause?. Dig Dis Sci 2007, 52:2015-2021.
3. Kruidenier L., Verspaget H.W. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous?. Aliment Pharmacol Ther 2002, 16:1997-2015.
4. Simmonds N.J., Allen R.E., Stevens T.R., Van Someren R.N., Blake D.R., Ramptom D.S. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 1992, 103:186-196.
5. Catarzi S., Favilli F., Romagnoli C., Marcucci T., Picariello L., Tonelli F., et al. Oxidative state and IL-6 production in intestinal myofibroblasts of Crohn's disease patients. Inflamm Bowel Dis 2011, 17:1674-1684.
6. Beltrán B., Nos P., Dasí F., Iborra M., Bastida G., Martínez M., et al. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naïve and treated Crohn's disease. Inflamm Bowel Dis 2010, 16:76-86.
7. Torres M.I., Ríos A. Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. World J Gastroenterol 2008, 14:1972-1980.
8. Iborra M., Moret I., Rausell F., Bastida G., Aguas M., Cerrillo E., et al. Role of oxidative stress and antioxidant enzymes in Crohn's disease. Biochem Soc Trans 2011, 39:1102-1106.
9. Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., Ames B.N. Bilirubin is an antioxidant of possible physiological importance. Science 1987, 235:1043-1046.
10. Stocker R., Glazer A.N., Ames B.N. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci U S A 1987, 84:5918-5922.
11. Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem 2000, 46:1723-1727.
12. Horsfall L.J., Rait G., Walters K., Swallow D.M., Pereira S.P., Nazareth I., et al. Serum bilirubin and risk of respiratory disease and death. JAMA 2011, 305:691-697.
13. Zucker S.D., Horn P.S., Sherman K.E. Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology 2004, 40:827-835.
14. Temme E.H., Zhang J., Schouten E.G., Kesteloot H. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 2001, 12:887-894.
15. Bosma P.J., Chowdhury J.R., Bakker C., Gantla S., de Boer A., Oostra B.A., et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995, 333:1171-1175.
16. Monaghan G., Ryan M., Seddon R., Hume R., Burchell B. Genetic variation in bilirubin UPD glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996, 347:578-581.
17. Bosma P.J. Inherited disorders of bilirubin metabolism. J Hepatol 2003, 38:107-117.
18. Chen Y.H., Hung S.C., Tarng D.C. Serum bilirubin links UGT1A1*28 polymorphism and predicts long-term cardiovascular events and mortality in chronic hemodialysis patients. Clin J Am Soc Nephrol 2011, 6:567-574.
19. Raijmakers M.T.M., Jansen P.L.M., Steegers E.A.P., Peters W.H.M. Association of human liver bilirubin UDP-glucuronosyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 2000, 33:348-351.
20. Peters W.H.M., te Morsche R.H.M., Roelofs H.M.J. Combined polymorphisms in UDP glucuronosyltransferases 1A1 and 1A6: implications for patients with Gilbert's syndrome. J Hepatol 2003, 38:3-8.
21. Johnson A.D., Kavousi M., Smith A.V., Chen M.H., Dehghan A., Aspelund T., et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet 2009, 18:2700-2710.
22. Bielinski S.J., Chai H.S., Pathak J., Talwalkar J.A., Limburg P.J., Gullerud R.E., et al. Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels. Mayo Clin Proc 2011, 86:606-614.
23. Seiderer J., Zech C.J., Diebold J., Schoenberg S.O., Brand S., Tillack C., et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur J Gastroenterol Hepatol 2006, 18:553-555.
24. Lee S., Mcleod H.L. Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. J Pathol 2011, 223:15-27.
25. Burger D., Travis S.P.L. Conventional medical management of inflammatory bowel disease. Gastroenterology 2011, 140:1827-1837.
26. Podolsky D.K. Inflammatory bowel disease. New Engl J Med 2002, 347:417-429.
27. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19:5A-36A.
28. de Vries H.S., te Morsche R.H.M., van Oijen M.G.H., Nagtegaal I.D., Peters W.H.M., de Jong D.J. The functional 765G→C polymorphism of the Cox-2 gene may reduce the risk of developing Crohn's disease. PLoS One 2010, 5:e15011.
29. Lacko M., Roelofs H.M.J., te Morsche R.H.M., Voogd A.C., Oude Ophuis M., Peters W.H.M., et al. Genetic polymorphism in the conjugating enzyme UGT1A1 and the risk of head and neck cancer. Int J Cancer 2010, 127:2815-2821.
30. Zintzaras E. The generalized odds ratio as a measure of genetic risk effect in the analysis and meta-analysis of association studies. Stat Appl Genet Mol Biol 2010, 9. Article21.
31. Rauchschwalbe S.K., Zühlsdorf M.T., Schühly U., Kuhlmann J. Predicting the risk of sporadic elevated bilirubin levels and diagnosing Gilbert's syndrome by genotyping UGT1A1*28 promoter polymorphism. Int J Clin Pharmacol Ther 2002, 40:233-240.
32. Koutroubakis I.E., Malliaraki N., Dimoulios P.D., Karmiris K., Castanas E., Kouroumalis E.A. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig Dis Sci 2004, 49:1433-1437.
33. Naito Y., Takagi T., Yoshikawa T. Heme oxygenase-1: a new therapeutic target for inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20(Suppl. 1):177-184.
34. Sheikh S.Z., Hegazi R.A., Kobayashi T., Onyiah J.C., Russo S.M., Matsuoka K., et al. An anti-inflammatory role for carbon monoxide and heme oxygenase-1 in chronic th2-mediated murine colitis. J Immunol 2011, 186:5506-5513.
35. Hegazi R.A., Rao K.N., Mayle A., Sepulveda A.R., Otterbein L.E., Plevy S.E. Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J Exp Med 2005, 202:1703-1713.
36. Lozovoy M., Simão A., Panis C., Rotter M., Reiche E., Morimoto H., et al. Oxidative stress is associated with liver damage, inflammatory status, and corticosteroid therapy in patients with systemic lupus erythematosus. Lupus 2011, 20:1250-1259.
37. Wruck C.J., Fragoulis A., Gurzynski A., Brandenburg L.O., Kan Y.W., Chan K., et al. Role of oxidative stress in rheumatoid arthritis: insights from the Nrf2-knockout mice. Ann Rheum Dis 2011, 70:844-850.
38. Fischman D., Valluri A., Gorrepati V.S., Murphy M.E., Peters I., Cheriyath P. Bilirubin as a protective factor for rheumatoid arthritis: an NHANES study of 2003-2006 data. J Clin Med Res 2010, 2:256-260.
39. Vítek L., Muchová L., Jancová E., Pesicková S., Tegzová D., Peterová V., et al. Association of systemic lupus erythematosus with low serum bilirubin levels. Scand J Rheumatol 2010, 39:480-484.
40. Motterlini R., Otterbein L.E. The therapeutic potential of carbon monoxide. Nature Rev Drug Disc 2010, 9:728-743.
41. Berberat P.O., A-Rahim Y.I., Yamashita K., Warny M.M., Csizmadia E., Robson S.C., et al. Heme oxygenase-1-generated biliverdin ameliorates experimental murine colitis. Inflamm Bowel Dis 2005, 11:350-359.
42. Varga C., Laszlo F., Fritz P., Cavicchi M., Lamarque D., Horvath K., et al. Modulation by heme and zinc protoporphyrin of colonic heme oxygenase-1 and experimental inflammatory bowel disease in the rat. Eur J Pharmacol 2007, 561:164-171.
43. Ford L.T., Berg J.D. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J Clin Pathol 2010, 63:288-295.
44. Dong X.W., Zheng Q., Zhu M.M., Tong J.L., Ran Z.H. Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroenterol 2010, 16:3187-3195.
45. Bourgine J., Garat A., Allorge D., Crunelle-Thibaut A., Lo-Guidice J.M., Colombel J.F., et al. Evidence for a functional genetic polymorphism of the Rho-GTPase Rac1. Implication in azathioprine response?. Pharmacogenet Genomics 2011, 21:313-324.
46. Borucki K., Weikert C., Fisher E., Jakubiczka S., Luley C., Westphal S., et al. Haplotypes in the UGT1A1 gene and their role as genetic determinants of bilirubin concentration in healthy German volunteers. Clin Biochem 2009, 42:1635-1641.